非冠状动脉旁路移植心脏手术后小剂量秋水仙碱的随机对照试验
该随机对照试验纳入132例非CABG心脏手术患者,最终秋水仙碱组59例、安慰剂组62例完成分析。秋水仙碱从术前72小时开始至术后5天,每日0.5 mg。主要终点术后48小时cTnT在秋水仙碱组显著低于安慰剂组(中位0.3 μg/L vs 0.4 μg/L,P<0.01)。次要终点cTnI、CK-MB、IL-6亦显著降低,心包切开后综合征发生率显著下降(3.08% vs 17.7%,P<0.01),但腹泻发生率显著增加(9.23% vs 0,P=0.01)。
要点
- 非CABG心脏手术患者围术期口服秋水仙碱0.5 mg每日(术前72小时至术后5天),术后48小时cTnT中位0.3 μg/L vs 安慰剂0.4 μg/L(P<0.01)。
- 秋水仙碱组术后48小时cTnI中位0.9 ng/ml vs 安慰剂1.3 ng/ml(P=0.02),CK-MB中位1.9 ng/ml vs 4.4 ng/ml(P<0.01)。
- 秋水仙碱组IL-6中位73.5 pg/ml vs 安慰剂101 pg/ml(P=0.048),提示炎症反应减轻。
- 秋水仙碱组心包切开后综合征发生率3.08% vs 安慰剂17.7%(P<0.01),但腹泻发生率9.23% vs 0(P=0.01)。
- 两组30天死亡率、卒中、ECMO和IABP使用等其他不良事件无显著差异。
适用人群与场景
- 接受非冠状动脉旁路移植(non-CABG)心脏手术且使用体外循环的患者。
- 排除因腹泻(n=6)和主动脉阻断时间>2小时(n=5)未纳入分析者。
处置流程与药物剂量
- 秋水仙碱组:从计划心脏手术前72小时开始口服秋水仙碱0.5 mg每日,持续至术后5天。
- 安慰剂组:接受安慰剂。
红旗征与不能漏的情况
- 腹泻:秋水仙碱组发生率9.23%(6/65),安慰剂组0(P=0.01),需监测并及时处理。
研究设计与关键结果
- 随机对照试验,最终分析秋水仙碱组59例、安慰剂组62例;主要终点术后48小时cTnT中位数秋水仙碱组0.3 μg/L(IQR 0.2-0.4)vs 安慰剂组0.4 μg/L(IQR 0.3-0.6),P<0.01。
- 术后48小时cTnI中位数秋水仙碱组0.9 ng/ml(IQR 0.4-1.7)vs 安慰剂组1.3 ng/ml(IQR 0.6-2.3),P=0.02。
- 术后48小时CK-MB中位数秋水仙碱组1.9 ng/ml(IQR 0.7-3.2)vs 安慰剂组4.4 ng/ml(IQR 1.5-8.2),P<0.01。
- 术后48小时IL-6中位数秋水仙碱组73.5 pg/ml(IQR 49.6-125.8)vs 安慰剂组101 pg/ml(IQR 57.5-164.7),P=0.048。
- 安全性:秋水仙碱组(n=65)心包切开后综合征发生率3.08% vs 安慰剂组(n=62)17.7%,P<0.01;腹泻发生率9.23% vs 0,P=0.01;其他不良事件(30天死亡率、卒中、ECMO和IABP使用等)两组无显著差异。
证据类型、等级与局限
- 研究类型:随机对照试验。
- 试验注册号:ChiCTR2000040129,注册日期2020年11月22日,首例受试者入组前注册。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,短期围术期小剂量秋水仙碱可有效减轻非CABG心脏手术后心肌损伤和炎症生物标志物,并减少心包切开后综合征。
- 使用秋水仙碱时需警惕腹泻风险增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Recent high-quality trials have shown that the anti-inflammatory effects of colchicine reduce the risk of cardiovascular events in patients suffering post-myocardial infarction and chronic coronary disease. The effect of colchicine in patients undergoing non-coronary artery bypass grafting (non-CABG) with cardiopulmonary bypass remains unclear. We aim to evaluate the effect of colchicine on myocardial protection in patients who underwent non-CABG cardiac surgery.
METHOD: Patients were randomly assigned to colchicine or placebo groups starting 72 h before scheduled cardiac surgery and for 5 days thereafter (0.5 mg daily).The primary outcome was the level of cardiac troponin T (cTnT) at postoperative 48 h. The secondary outcomes included troponin I (cTnI) and creatine kinase-MB (CK-MB), inflammatory biomarkers (procalcitonin and interleukin-6, etc.), and adverse events (30-day mortality, stroke, ECMO and IABP use, etc.).
RESULTS: A total of 132 patients underwent non-CAGB cardiac surgery, 11were excluded because of diarrhea (n = 6) and long aortic cross-clamp time > 2 h (n = 5), 59 were assigned to the colchicine group and 62 to the placebo group. Compared with the placebo group, cTnT (median: 0.3 μg/L, IQR 0.2-0.4 μg/L vs. median: 0.4 μg/L, IQR 0.3-0.6 μg/L, P < 0.01), cardiac troponin I (median: 0.9 ng/ml, IQR 0.4-1.7 ng/ml vs. median: 1.3 ng/ml, IQR 0.6-2.3 ng/ml, P = 0.02), CK-MB (median: 1.9 ng/ml, IQR 0.7-3.2 ng/ml vs. median: 4.4 ng/ml, IQR 1.5-8.2 ng/ml, P < 0.01), and interleukin-6 (median: 73.5 pg/ml, IQR 49.6-125.8 pg/ml vs. median: 101 pg/ml, IQR 57.5-164.7 pg/ml, P = 0.048) were significantly reduced in colchicine group at postoperative 48 h. For safety evaluation, the colchicine (n = 65) significantly decreased post-pericardiotomy syndrome (3.08% vs. 17.7%, P < 0.01) and increased the rate of diarrhea (9.23% vs. 0, P = 0.01) compared with the placebo group (n = 62). No significant difference was observed in other adverse events between the two groups.
CONCLUSION: A short perioperative course of low-dose colchicine was effective to attenuate the postoperative biomarkers of myocardial injury and inflammation, and to decrease the postoperative syndrome compared with the placebo. Trial registration ChiCTR2000040129. Registered 22nd Nov. 2020. This trial was registered before the first participant was enrolled. http://www.chictr.org.cn/showproj.aspx?proj=64370 .
参考来源
- Pan T, Jiang CY, Zhang H, et al. The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial. Crit Care. 2023. PMID: 36747296. doi:10.1186/s13054-023-04341-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。